Premier Alternatives

Trethera

Sherman Oaks, CA · Founded 2015 · Privately Held (backing)

Developer of nucleotide metabolism drugs designed to provide treatment for cancer and autoimmune diseases. Trethera is based in Sherman Oaks, CA and was founded in 2015. Its last reported valuation was $13.1 million in Apr 2019. It has raised $35 million across 7 recorded rounds; the latest was a $250,000 seed round in Apr 2025.

Last reported valuation
$13.1M
Oct 2026
Priced at
—
Total raised
$35.0M
Last round
Seed Round
Apr 2025

Trethera key facts

as of Oct 2026
  • Developer of nucleotide metabolism drugs designed to provide treatment for cancer and autoimmune diseases.
  • Trethera is valued at approximately $13.1M as of Oct 2026 (last reported valuation).
  • It has raised $35.0M across 7 recorded rounds; the latest was Seed Round ($250K) in Apr 2025.
  • Notable investors include National Institutes of Health, Libertatis Ergo Holding (LEH), LifeSciences@Work, National Cancer Institute, National Eye Institute — 7 tracked in total.
  • Trethera has filed 8 Form Ds with the SEC since 2016, most recently May 2025 ($250K sold to 1 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$13.1M

Trethera's last reported valuation, Apr 2019. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Trethera with a free account
  • ·Watch Trethera: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Trethera funding rounds

7 rounds
Apr 2025Seed Round$250KSEC filing▮
Jun 2021Seed Round$3.8MSEC filing▮
Feb 2020Seed Round$3.3MSEC filing▮
Apr 2019Seed Round$581KSEC filing▮
Mar 2019Early Stage VC$8.1MSEC filing▮
Full funding history →

Trethera valuation

Trethera's last reported valuation was $13.1 million in Apr 2019. No priced round, secondary trade or fund mark has surfaced since.

How much has Trethera raised?

Trethera has raised $35 million across 7 recorded rounds since 2016. The largest was an $8.1 million early-stage round in Mar 2019; the most recent was a $250,000 seed round in Apr 2025.

Trethera has filed 8 Form Ds with the SEC since 2016, most recently in May 2025 ($250,000 sold to 1 investor).

Trethera investors

7 investors are on record for Trethera, including National Institutes of Health, Libertatis Ergo Holding (LEH), LifeSciences@Work and National Cancer Institute. The seed round in Apr 2025 drew 1 investor.

About Trethera

Developer of nucleotide metabolism drugs designed to provide treatment for cancer and autoimmune diseases. The company's drugs are deoxycytidine kinase inhibitor that improves bioavailability and demonstrates anti-tumor activity in combination therapies, enabling patients to avail of drugs that improve treatment efficacy and overcome the limitations of single-agent therapies.

Sector
Healthcare
HQ
Sherman Oaks, CA, United States
Founded
2015
Employees
9
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.